13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001831942
Total reported value
$1.7B
$1.7B
35 檔
35.8%
As reported in its official Q2 2024 Form 13F filing, Commodore Capital LP's tracked investment portfolio stood at $1.7B with 35 total positions.
During Q2 2024, Commodore Capital LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including MERUS N V, NUVL, XENE) accounted for 35.8% of total reported equity market value during Q2 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | Stock-Other | 12.92% | — | -26.61% | |
| 2 | NUVL | Nuvalent Inc-a | Stock-Other | 7.70% | -4.20% | — | |
| 3 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 7.33% | -2.78% | EXIT | |
| 4 | PCVX | Vaxcyte Inc | Stock-Other | 6.73% | — | +51.74% | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.34% | +2.47% | — | |
| 6 | VERA | Vera Therapeutics Inc | Stock-Other | 6.11% | — | -21.80% | |
| 7 | COGT | Cogent Biosciences Inc | Stock-Other | 5.60% | +0.60% | +51.56% | |
| 8 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.97% | -1.26% | EXIT | |
| 9 | CLDX | Celldex Therapeutics Inc | Stock-Other | 3.60% | -1.96% | +64.46% | |
| 10 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.52% | — | +22.50% | |
| 11 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.43% | — | +16.67% | |
| 12 | ARVN | Arvinas Inc | Stock-Other | 3.42% | — | +47.79% | |
| 13 | SYRE | Spyre Therapeutics Inc | Stock-Other | 3.19% | -1.10% | +5.52% | |
| 14 | CATX | Perspective Therapeutics Inc | Stock-Other | 3.17% | -0.24% | — | |
| 15 | PHVS | Pharvaris N.V. | Stock-Other | 2.32% | -0.21% | +4.94% | |
| 16 | ALKS | Alkermes plc | Stock-Healthcare | 2.26% | +0.77% | — | |
| 17 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.25% | — | +30.67% | |
| 18 | KURA | Kura Oncology Inc | Stock-Other | 2.24% | — | +4.48% | |
| 19 | NKTX | Nkarta Inc | Stock-Other | 1.67% | — | +31.15% | |
| 20 | CELC | Celcuity Inc | Stock-Other | 1.64% | — | -5.90% | |
| 21 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.37% | — | +23.63% | |
| 22 | IMVT | Immunovant Inc | Stock-Other | 1.35% | — | — | |
| 23 | ABVX | Abivax Sa-adr | Stock-Other | 1.16% | — | -32.24% | |
| 24 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.16% | — | +158.74% | |
| 25 | CCCC | C4 Therapeutics Inc | Stock-Other | 1.08% | — | — | |
| 26 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.97% | — | — | |
| 27 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.78% | — | — | |
| 28 | CABA | Cabaletta Bio Inc | Stock-Other | 0.56% | — | — | |
| 29 | ✓ | Stock-Other | 0.52% | — | — | ||
| 30 | NGNE | Neurogene Inc | Stock-Other | 0.50% | — | — | |
| 31 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.37% | +0.04% | NEW | |
| 32 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.35% | — | — | |
| 33 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.28% | — | -48.75% | |
| 34 | ABIOEUR | Arca Biopharma Inc | Stock-Other | 0.11% | — | — | |
| 35 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.03% | +0.70% | — |
According to official SEC Form 13F filings, Commodore Capital LP reported a total U.S. public equity portfolio value of $1.7B across 35 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q2 2024, Commodore Capital LP's top holdings by market value included MERUS N V (12.9%)、NUVL (7.7%)、XENE (7.3%). The largest single position, MERUS N V, represented 12.9% of total portfolio value.
In Q2 2024, Commodore Capital LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.